PerspectivePowder technology in the pharmaceutical industry: the need to catch up fast
Introduction
The picture is entirely familiar. It is late at night, time for your child's medication. You open a small container, take a pill, and give it to your daughter or son. You go to sleep. You know that everything will be fine.
Astounding advances in medicine (beginning with the advent of modern antibiotics), reinforced by more than 50 billion dollars per year in worldwide advertising by drug companies, have led us to think of drugs as perfect products. We routinely consume tablets and capsules, expecting them to contain precisely what they are supposed to and to perform exactly as intended. If anything, we might be concerned about allergic reactions, i.e., our body experiencing the “wrong” reaction to the medicine, but questions such as “Is this pill OK? Does it contain the specified dose of drug? Has it been properly manufactured? Will it perform as intended?” rarely cross our minds. This is striking, considering that drug substances are highly toxic compounds. In some sense, they cure disease because they are toxic; i.e., because they have the ability to dramatically affect human physiology. In fact, the more potent the drug, the more toxic. Thus, health risks are an intrinsic, unavoidable component of pharmacological therapies. When we take medications, we are consuming potentially dangerous substances, and we can only hope that the processes used to make them are sufficiently well understood and controlled to make those risks as small as possible.
Is our faith in drug products justified? The answer is yes, but with qualifications. As part of the process of introducing new drugs to the market, industry and government go through tremendous efforts involving multiple stages of clinical trials to determine drug therapeutic benefits, optimum dose, and incidence of side effects. However, as discussed below, the technology used to manufacture drug products can at best be described as primitive. We only have a partial understanding of the materials and processes involved in pharmaceutical product development and manufacturing, which are carried out largely by empirical methods. Thus, the inherent reliability of pharmaceutical manufacturing is highly questionable, and is likely to be increasingly challenged in the near future. In the past, economics often led pharmaceutical companies to emphasize discovery, or mere advertising, at the expense of technology research. However, in the future the relative priorities will change as manufacturing challenges become substantial enough to have significant impact on the ability of companies to make certain products at all.
Early in clinical trials, companies determine the target concentration of drug in the bloodstream as a function of time. Subsequently, through a process termed “formulation”, they develop a dosage form (a tablet, a capsule, an aerosol, an injectable product, etc.) that will express the desired amount of drug as a function of time in the bloodstream of the “average person”. Thus, a drug product involves much more than a package containing the right amount of a compound; it is also a delivery system intended to interact with the human body in a specific manner. For example, many drugs are sensitive to pH and therefore must be engineered to be absorbed in the environment of the intestine, but not the stomach, or vice versa. Likewise, long chain proteins become degraded in the gut and must be delivered as inhalants, in which case, ensuring transport to the deep lung becomes important.
Increasingly, companies devote substantial efforts to understanding and controlling the factors that affect the delivery of the drug substance to the desired point of action. In fact, effective drug delivery is rapidly becoming a decisive factor in determining drug product effectiveness. Recent advances in molecular genetics are accelerating the discovery of much more potent and specifically targeted molecules that also tend to be larger, less soluble, less permeable, and more vulnerable to the body's enzymatic circuit. Increasingly, these compounds need to be quantitatively delivered at a precise location within the body at a carefully controlled rate in order to be safe and effective.
As a result, most major pharmaceutical companies have developed extensive research programs in drug delivery, both in-house and at academic institutions. However, much less effort is devoted to the technology used to manufacture drug products. Once a dosage form is designed, companies develop a batch manufacturing process in order to make a large number (typically millions) of units with properties (drug content, tablet hardness, dissolution, stability) within certain tolerance margins. This process is typically performed using empirical scale-up methods to translate formulation information into large-scale routine manufacturing. Given our limited understanding of human physiology, material science, and the interactions between the body and drug substances in the presence of other ingredients, the design and timely manufacture of millions of units of a drug product all having the same composition and physicochemical attributes is, both in principle and in practice, an increasingly daunting task, pregnant with enormous potential for both human and economic disaster.
At its core, the US FDA drug approval process challenges companies to manufacture a few (typically three) production-scale batches according to specifications that sometimes are set by the companies themselves. Once this is accomplished, the process is deemed “validated” and is intended to be repeated, without changes, indefinitely. In other words, once a drug product is developed, a method for its manufacture is determined, and it is reproduced three times within specifications, both industry and government are loath to introduce the slightest change in the manufacturing method, because of the numerous uncertainties involved. Simply put, neither industry nor governmental agencies know what would happen, and any changes might necessitate onerous testing and retesting to ensure that in vivo performance has not been adversely affected.
In order to protect the public from potential risks, companies are required (to a varying degree, depending on the type of product) to develop monitoring methods intended to control materials and processes and minimize undesirable changes. Unfortunately, as it is the case in most human enterprises, change is unavoidable, especially when we do not know the impact of many variables that go unmonitored, or even further, that cannot be monitored given the state of available technology.
It is thus clear that a much better understanding of pharmaceutical products, ingredients, and manufacturing processes is sorely needed. Much of the work to be done is in the area of powder technology. To make this point clear, let us briefly review how drugs are made.
Section snippets
The pharmaceutical manufacturing sequence
A representative (albeit not unique) sequence of operations involved in making tablets and capsules (which comprise roughly 80% of all pharmaceutical products destined for US consumption) is depicted in Fig. 1.
As is immediately apparent, the manufacturing process is largely “powder technology”, under a variety of guises. The entire sequence of operations is devoted to making particles, modifying their properties, and then turning them into structured products. A partial list of classic
Outlook: particle technology as a competitive advantage
From the above discussion, it is clear that concentrated efforts in particle technology should play a major role in the research strategies of pharmaceutical companies over the next decade (and beyond). This will strongly affect the two factors that have the largest effect on profitability: time to market, and length of patent protection. Simply put, unless companies significantly develop their capabilities to characterize, control, and optimize particle properties at every step of the
Conclusions
Due predominantly to historical reasons, the academic engineering community has largely ignored pharmaceutical processes, from both educational and research perspectives (the only exemptions being synthesis and crystallization). Until recently, engineers have been largely missing from pharmaceutical formulation and manufacturing areas. The end result is an industry where both products and processes are designed largely by empiricism, and where the level of understanding is so incomplete that
References (22)
- et al.
Model identification for crystallization: theory and experimental verification
Powder Technol.
(1996) - et al.
Crystallization processes in pharmaceutical technology and drug delivery design
J. Cryst. Growth
(2000) - et al.
Advances in pharmaceutical materials and processing
Pharm. Sci. Technol. Today
(1998) - et al.
Vacuum drying of a multicomponent pharmaceutical product having different pseudo-polymorphic forms
Chem. Eng. Process.
(1999) - et al.
Nucleation, growth and breakage phenomena in agitated wet granulation processes: a review
Powder Technol.
(2001) - et al.
Use of stress fluctuations to monitor wet granulation of powders
Powder Technol.
(2001) Fundamental powder mixing mechanisms
Powder Technol.
(1976)- et al.
Mixing dynamics in catalyst impregnation in double-cone blenders
Powder Technol.
(1999) - et al.
Experimentally validated computations of flow, mixing and segregation of non-cohesive grains in 3D tumbling blenders
Powder Technol.
(2000) - et al.
Forces generated in solidifying liquid bridges between two small particles
Powder Technol.
(1996)
Non-uniformity of coating on a size distribution of particles in a fluidized bed coater
Powder. Technol.
Cited by (220)
On the flow of soft suspensions through orifices
2023, Computers and FluidsA review of recent development for the CFD-DEM investigations of non-spherical particles
2022, Powder TechnologyECVT study of 3D flow characteristics at L-shaped exit of CFB riser
2022, Chemical Engineering Science